451 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity

• William Redmond,
• Annah Rolig,
• Daniel Rose,
• Saul Kivimae,
• Werner Rubas

Affiliations

William Redmond

1Earle A. Chiles Research Institute, Portland, OR, USA

Annah Rolig

1Earle A. Chiles Research Institute, Portland, OR, USA

Daniel Rose

1Earle A. Chiles Research Institute, Portland, OR, USA

Saul Kivimae

2Nektar Therapeutcs, San Francisco, CA, USA

Werner Rubas

2Nektar Therapeutcs, San Francisco, CA, USA